Adsorptive cytapheresis for ulcerative colitis with focus on removing platelets and platelet‐aggregates. Issue 3 (10th November 2022)

• Record Type: Journal Article
• Authors: Schneider, Matthias; Waitz, Grit; Prophet, Heinrich; Schober, Hans‐Christof; Ramlow, Wolfgang
• Is Part Of: Therapeutic apheresis and dialysis. Volume 27:Issue 3(2023)
• Page Start: 452
• Page End: 463
• Publication Date: 2022-11-10
• Subjects: apheresis -- colitis ulcerosa -- Immunopure -- platelet leukocyte aggregates (PLAs) -- platelets; Hemapheresis -- Periodicals; Dialysis -- Periodicals; Blood Component Removal -- Periodicals; Renal Dialysis -- Periodicals; Hémaphérèse -- Périodiques; Dialyse -- Périodiques; Sang -- Collecte et conservation -- Périodiques; 616
• DOI: 10.1111/1744-9987.13942
• Languages: English
• ISSNs: 1744-9979

Abstract

Abstract: Introduction: Platelet abnormalities and secondary thrombocytosis are clinical features of ulcerative colitis (UC) and seem to play a relevant role in pathogenesis. This work analyzed the adsorption characteristics of the adsorber Immunopure. Methods: A prospective study was performed to investigate the module in vitro with blood from healthy donors in a down‐scaled recirculation model and in vivo in six patients suffering from UC. Furthermore, adsorber beads were investigated by immunofluorescence analyses. Apheresis was performed over 5 weeks at weekly intervals. Results: In vitro as well as in vivo, the module showed a strong adsorption of platelets, monocytes, CD14 + CD16 + monocytes, neutrophils, and platelet leukocyte aggregates (PLAs). Five of the six patients benefited from the treatment (83%), and four (67%) went into remission. On average, the CAI was reduced by 6.4 points. Conclusion: Immunopure treatments improved the course of the disease and were well tolerated. The module strongly adsorbs platelets and platelet‐aggregates.